Volpara and Lunit co-host session on reducing interval cancers with AI
"Breast imaging has long been at the forefront of technology adoption. And yet when it comes to demonstrating compliance with MQSA”which has high stakes”mammography centers rely on stacks of binders and manual, repetitive and tiresome processes," says
Quiver helps quality assurance leaders ensure everything is in order well in advance of inspection day. Quiver set up is auto populated with clinic, mammography system and technologist activity from Volpara ® Analytics™ software. The software is accessible from any web browser and provides a clinic by clinic look at technologists' continuing education records and mammography system quality assurance documentation. Technologists can upload their own records and email notifications can alert staff when their credits are about to expire. Free credits are also available through Volpara ® Hive™, an online community exclusively for Volpara customers. All documentation can be presented to inspectors digitally or printed.
Reducing interval cancers with AI and personalized screening
Volpara previously announced it entered into a Scheme Implementation Agreement with Lunit ®. At SBI the companies are co-hosting a Learning Lab session titled, "Reducing interval cancers with AI and personalized screening." on
To see a Quiver demonstration and Volpara's other latest software advancements for breast centers visit booth #118 at SBI 2024.
About Volpara Health (ASX: VHT)
Volpara Health makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations, compliance preparation and provides key performance insights that support continuous quality improvement.
Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,600 technologists, impacting nearly 17 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in
For more information, visit www.volparahealth.com.